West Pharma earnings show it's more than a GLP-1 play. Why we see more upside
Since CNBC highlighted the stock's attractive valuation in August, shares have gained around 20%. Why we expect more upside ahead.
Since CNBC highlighted the stock's attractive valuation in August, shares have gained around 20%. Why we expect more upside ahead.
Read the full article on CNBC
Read Full Article →